127 results
424B5
AADI
Aadi Bioscience Inc
3 May 24
Prospectus supplement for primary offering
4:05pm
not been fully exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.
On November 22 … , including investigator-assessed response and safety analyzed separately in each of the TSC1 and TSC2 arms. Nine different tumor types were enrolled
8-K
EX-99.1
AADI
Aadi Bioscience Inc
13 Mar 24
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
8:08am
arms. The safety profile was consistent with the nab-sirolimus label and the mTOR inhibitor drug class.
Enrollment of two single-indication Phase 2 … and continued advancements, including in potential additional indications; expectations regarding the beneficial characteristics, safety, efficacy
8-K
EX-99.2
b4weu
14 Dec 23
80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024
5:08pm
8-K
EX-99.1
dp4vwiv8l
14 Dec 23
80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024
5:08pm
8-K/A
EX-99.1
507vbu9
8 Nov 23
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
4:28pm
8-K
EX-99.1
mnqna1d31e1lh
2 Oct 23
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
8:30am
8-K
EX-99.1
c49zqxg5n7
9 Aug 23
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides
8:05am
8-K
EX-99.1
15jf9xnud5k8q9qikxe
10 May 23
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
8:07am
8-K
EX-99.1
wx5649zff75mjy1
9 Nov 22
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
8:19am
424B3
jov7 jp2a
4 Nov 22
Prospectus supplement
4:05pm
8-K
EX-99.1
6fwvd6p nbm0rmjj6g
22 Sep 22
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
4:38pm